162 related articles for article (PubMed ID: 15205563)
21. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
22. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
23. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
Gerich J; Raskin P; Jean-Louis L; Purkayastha D; Baron MA
Diabetes Care; 2005 Sep; 28(9):2093-9. PubMed ID: 16123472
[TBL] [Abstract][Full Text] [Related]
24. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M
Diabetes Obes Metab; 2003 Jan; 5(1):38-44. PubMed ID: 12542723
[TBL] [Abstract][Full Text] [Related]
25. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
Hollander P; Lasko B; Barnett AH; Bengus M; Kanitra L; Pi-Sunyer FX; Balena R
Obesity (Silver Spring); 2013 Feb; 21(2):238-47. PubMed ID: 23404788
[TBL] [Abstract][Full Text] [Related]
26. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.
Skillman CA; Raskin P
Diabetes Care; 1997 Apr; 20(4):591-6. PubMed ID: 9096985
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial.
Safarpour P; Daneshi-Maskooni M; Vafa M; Nourbakhsh M; Janani L; Maddah M; Amiri FS; Mohammadi F; Sadeghi H
BMC Fam Pract; 2020 Feb; 21(1):26. PubMed ID: 32033527
[TBL] [Abstract][Full Text] [Related]
28. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Fonseca V; Rosenstock J; Patwardhan R; Salzman A
JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial.
Ghosh A; Sengupta N; Sahana P; Giri D; Sengupta P; Das N
Indian J Pharmacol; 2014; 46(1):24-8. PubMed ID: 24550580
[TBL] [Abstract][Full Text] [Related]
30. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
Garber AJ; Bruce S; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
[TBL] [Abstract][Full Text] [Related]
31. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
32. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
Chamarthi B; Ezrokhi M; Rutty D; Cincotta AH
Postgrad Med; 2016 Nov; 128(8):761-769. PubMed ID: 27687032
[TBL] [Abstract][Full Text] [Related]
33. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
34. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
[TBL] [Abstract][Full Text] [Related]
35. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
37. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
[TBL] [Abstract][Full Text] [Related]
38. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.
Babar M; Hussain M; Ahmad M; Akhtar L
J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526
[TBL] [Abstract][Full Text] [Related]
39. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial.
Pattzi HM; Pitale S; Alpizar M; Bennett C; O'Farrell AM; Li J; Cherrington JM; Guler HP;
Diabetes Obes Metab; 2010 Apr; 12(4):348-55. PubMed ID: 20380656
[TBL] [Abstract][Full Text] [Related]
40. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes.
Hussain SA
J Med Food; 2007 Sep; 10(3):543-7. PubMed ID: 17887949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
